Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
04
10
2023
accepted:
28
02
2024
revised:
23
02
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to elucidate the impact of amino-terminal modifications to the 5-MeO-DMT molecule on its interactions with serotonin receptors and transporters, as well as its psychoactive and thermoregulatory properties. Our findings demonstrated, using radioligand binding methodologies, that all examined 5-MeO-tryptamines exhibited selectivity for 5-HT1AR over 5-HT2AR. In fact, computational docking analyses predicted a better interaction in the 5-HT1AR binding pocket compared to 5-HT2AR. Our investigation also proved the interaction of these compounds with SERT, revealing that the molecular size of the amino group significantly influenced their affinity. Subsequent experiments involving serotonin uptake, electrophysiology, and superfusion release assays confirmed 5-MeO-pyr-T as the most potent partial 5-HT releaser tested. All tested tryptamines elicited, to some degree, the head twitch response (HTR) in mice, indicative of a potential hallucinogenic effect and mainly mediated by 5-HT2AR activation. However, 5-HT1AR was also shown to be implicated in the hallucinogenic effect, and its activation attenuated the HTR. In fact, tryptamines that produced a higher hypothermic response, mediated by 5-HT1AR, tended to exhibit a lower hallucinogenic effect, highlighting the opposite role of both 5-HT receptors. Moreover, although some 5-MeO-tryptamines elicited very low HTR, they still act as potent 5-HT2AR agonists. In summary, this research offers a comprehensive understanding of the psychopharmacological profile of various amino-substituted 5-MeO-tryptamines, keeping structural aspects in focus and accumulating valuable data in the frame of NPS. Moreover, the unique characteristics of some 5-MeO-tryptamines render them intriguing molecules as mixed-action drugs and provide insight within the search of non-hallucinogenic but 5-HT2AR ligands as therapeutical agents.
Identifiants
pubmed: 38486047
doi: 10.1038/s41380-024-02506-8
pii: 10.1038/s41380-024-02506-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Catalani V, Corkery JM, Guirguis A, Napoletano F, Arillotta D, Zangani C, et al. Psychonauts’ psychedelics: a systematic, multilingual, web-crawling exercise. Eur Neuropsychopharmacol. 2021;49:69–92.
pubmed: 33857740
doi: 10.1016/j.euroneuro.2021.03.006
EMCDDA. European monitoring centre for drugs and drug addiction (EMCDDA). European drug report: trends and developments. Publications Office of the European Union, 2022.
Reuter P, Pardo B. Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill. Addiction. 2017;112:25–31.
pubmed: 27220685
doi: 10.1111/add.13439
Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK. New psychoactive substances: a review and updates. Ther Adv Psychopharmacol. 2020;10:2045125320967197.
pubmed: 33414905
pmcid: 7750892
doi: 10.1177/2045125320967197
Soussan C, Kjellgren A. The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations. Int J Drug Policy. 2016;32:77–84.
pubmed: 27184218
doi: 10.1016/j.drugpo.2016.03.007
Gibbons S. ‘Legal Highs’ – novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol. 2012;50:15–24.
doi: 10.3109/15563650.2011.645952
Musselman ME, Hampton JP. ‘not for human consumption’: a review of emerging designer drugs. Pharmacotherapy. 2014;34:745–57.
pubmed: 24710806
doi: 10.1002/phar.1424
Tittarelli R, Mannocchi G, Pantano F, Romolo FS. Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol. 2015;13:26–46.
pubmed: 26074742
pmcid: 4462041
doi: 10.2174/1570159X13666141210222409
Nichols DE. Structure-activity relationships of serotonin 5-HT2A agonists. Wiley Interdiscip Rev Membr Transp Signal. 2012;1:559–79.
doi: 10.1002/wmts.42
Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology. 2018;142:231–9.
pubmed: 29499272
pmcid: 6230509
doi: 10.1016/j.neuropharm.2018.02.028
Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, et al. Pharmacologic activity of substituted tryptamines at 5-HT 2A R, 5-HT 2C R, 5-HT 1A R, and SERT. J Pharmacol Exp Ther. 2023;385:62–75.
pubmed: 36669875
pmcid: 10029822
doi: 10.1124/jpet.122.001454
Rogawaski M, Aghajanian G. Serotonin autoreceptors on dorsal raphe neurons: structure-activity relationships of tryptamine analogs. J Neurosci. 1981;1:1148–54.
pmcid: 6564212
doi: 10.1523/JNEUROSCI.01-10-01148.1981
Scherbaum N, Schifano F, Bonnet U. New psychoactive substances (NPS)—a challenge for the addiction treatment services. Pharmacopsychiatry 2017;50:116–22.
pubmed: 28444659
doi: 10.1055/s-0043-102059
Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, et al. Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:288–91.
pubmed: 16876302
doi: 10.1016/j.pnpbp.2006.06.012
Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci Int. 2006;163:152–4.
pubmed: 16406422
doi: 10.1016/j.forsciint.2005.11.026
Wilson JM, McGeorge F, Smolinske S, Meatherall R. A foxy intoxication. Forensic Sci Int. 2005;148:31–6.
pubmed: 15607587
doi: 10.1016/j.forsciint.2004.04.017
European Monitoring Centre for Drugs and Drug Addiction, Europol, New drugs in Europe, 2012 : EMCDDA–Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. Publications Office; 2013. Available from: doi/10.2810/99367
European Monitoring Centre for Drugs and Drug Addiction, Europol, EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA : in accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances: implementation reports. Publications Office; 2015. Available from: doi/10.2810/112317
European Monitoring Centre for Drugs and Drug Addiction, Europol, EMCDDA–Europol 2017 annual report on the implementation of Council Decision 2005/387/JHA : in accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. Publications Office; 2018. Available from: doi/10.2810/759319
Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Curr Top Behav Neurosci. 2016;36:361–91.
doi: 10.1007/7854_2016_464
Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;14:351–8.
pubmed: 36630260
doi: 10.1021/acschemneuro.2c00718
Heifets BD, Olson DE. Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology. 2024;49:104–18.
pubmed: 37488282
doi: 10.1038/s41386-023-01666-5
McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21:463–73.
pubmed: 35301459
doi: 10.1038/s41573-022-00421-7
Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem. 2022;162:128–46.
pubmed: 35149998
pmcid: 9314805
doi: 10.1111/jnc.15587
Erkizia-Santamaría I, Alles-Pascual R, Horrillo I, Meana JJ, Ortega JE. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed Pharmacother. 2022;154:113612.
pubmed: 36049313
doi: 10.1016/j.biopha.2022.113612
Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB. The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. Psychopharmacology. 2015;232:275–84.
pubmed: 24985890
doi: 10.1007/s00213-014-3658-3
Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Lotan A, et al. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: translational implications. Int J Mol Sci. 2022;23:14148.
pubmed: 36430623
pmcid: 9698447
doi: 10.3390/ijms232214148
Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB. Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology. 2014;231:4135–44.
pubmed: 24800892
pmcid: 4194234
doi: 10.1007/s00213-014-3557-7
Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559:132–7.
pubmed: 17223101
doi: 10.1016/j.ejphar.2006.11.075
Sogawa C, Sogawa N, Tagawa J, Fujino A, Ohyama K, Asanuma M, et al. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol Lett. 2007;170:75–82.
pubmed: 17382495
doi: 10.1016/j.toxlet.2007.02.007
Mayer FP, Niello M, Cintulova D, Sideromenos S, Maier J, Li Y, et al. Serotonin-releasing agents with reduced off-target effects. Mol Psychiatry. 2023;28:722–32.
pubmed: 36352123
doi: 10.1038/s41380-022-01843-w
Blier P, Piñeyro G, el Mansari M, Bergeron R, de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann N. Y Acad Sci. 1998;861:204–16.
pubmed: 9928258
doi: 10.1111/j.1749-6632.1998.tb10192.x
Nackenoff AG, Simmler LD, Baganz NL, Pehrson AL, Sánchez C, Blakely RD. Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed using the sert met172 mouse. ACS Chem Neurosci. 2017;8:1092–1100.
pubmed: 28272863
doi: 10.1021/acschemneuro.7b00038
Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharm Ther. 2002;95:73–88.
doi: 10.1016/S0163-7258(02)00234-6
Cozzi NV, Daley PF. Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines. Bioorg Med Chem Lett. 2016;26:959–64.
pubmed: 26739781
doi: 10.1016/j.bmcl.2015.12.053
Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. Investigation of the structure-activity relationships of psilocybin analogues. ACS Pharm Transl Sci. 2021;4:533–42.
doi: 10.1021/acsptsci.0c00176
Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327–37.
pubmed: 27216487
doi: 10.1016/j.euroneuro.2016.05.001
Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging ‘Novel Psychoactive Drugs. Bioorg Med Chem Lett. 2013;23:3411–5.
pubmed: 23602445
doi: 10.1016/j.bmcl.2013.03.066
Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharm Biochem Behav. 2006;83:122–9.
doi: 10.1016/j.pbb.2005.12.015
Gatch MB, Forster MJ, Janowsky A, Eshleman AJ. Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther. 2011;338:280–9.
pubmed: 21474568
pmcid: 3126641
doi: 10.1124/jpet.111.179705
Glatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, et al. Receptor binding profiles for tryptamine psychedelics and effects of 4-propionoxy- N,N -dimethyltryptamine in mice. ACS Pharm Transl Sci. 2023;6:567–77.
doi: 10.1021/acsptsci.2c00222
Glatfelter GC, Pottie E, Partilla JS, Sherwood AM, Kaylo K, Pham DNK, et al. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharm Transl Sci. 2022;5:1181–96.
doi: 10.1021/acsptsci.2c00177
Jiang XL, Shen HW, Yu AM. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. Neuropharmacology. 2015;89:342–51.
pubmed: 25446678
pmcid: 4310233
doi: 10.1016/j.neuropharm.2014.10.013
Williams MT, Herring NR, Schaefer TL, Skelton MR, Campbell NG, Lipton JW, et al. Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine (‘Foxy’) to adult rats: a new drug of abuse. Neuropsychopharmacology. 2007;32:1404–20.
pubmed: 17047665
doi: 10.1038/sj.npp.1301232
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40:1769–77.
pubmed: 32663096
pmcid: 7430098
doi: 10.1177/0271678X20943823
Nadal-Gratacós N, Alberto-Silva AS, Rodríguez-Soler M, Urquizu E, Espinosa-Velasco M, Jäntsch K, et al. Structure–activity relationship of novel second-generation synthetic cathinones: mechanism of action, locomotion, reward, and immediate-early genes. Front Pharm. 2021;12:749429.
doi: 10.3389/fphar.2021.749429
Brugnoli FR, Holy M, Niello M, Maier J, Hanreich M, Menzel M, et al. Development and validation of an automated microfluidic perfusion platform for parallelized screening of compounds in vitro. Basic Clin Pharm Toxicol. 2023;133:535–47.
doi: 10.1111/bcpt.13940
Duart-Castells L, Nadal-Gratacós N, Muralter M, Puster B, Berzosa X, Estrada-Tejedor R, et al. Role of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones. Neuropharmacology. 2021;186:108475.
pubmed: 33529677
doi: 10.1016/j.neuropharm.2021.108475
Nadal-Gratacós N, Lleixà E, Gibert-Serramià M, Estrada-Tejedor R, Berzosa X, Batllori X, et al. Neuropsychopharmacology of emerging drugs of abuse: meta-and para-halogen-ring-substituted α-PVP (“flakka”) derivatives. Int J Mol Sci. 2022;23:2226.
pubmed: 35216339
pmcid: 8876800
doi: 10.3390/ijms23042226
Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jørgensen TN, Holy M, et al. The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem. 2010;285:10924–38.
pubmed: 20118234
pmcid: 2856298
doi: 10.1074/jbc.M109.083154
Xu P, Huang S, Zhang H, Mao C, Zhou XE, Cheng X, et al. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature. 2021;592:469–73.
pubmed: 33762731
doi: 10.1038/s41586-021-03376-8
Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science. 2022;375:403–11.
pubmed: 35084960
doi: 10.1126/science.abl8615
Tylš F, Páleníček T, Kadeřábek L, Lipski M, Kubešová A, Horáček J. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharmacol. 2016;27:309–20.
pubmed: 26461483
doi: 10.1097/FBP.0000000000000198
Yung-Chi C, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharm. 1973;22:3099–108.
doi: 10.1016/0006-2952(73)90196-2
Halberstadt AL, Chatha M, Chapman SJ, Brandt SD. Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. J Psychopharmacol. 2019;33:406–14.
pubmed: 30789291
pmcid: 6848748
doi: 10.1177/0269881119826610
Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH. Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharm Exp Ther. 2000;293:870–8.
Bhat S, Niello M, Schicker K, Pifl C, Sitte HH, Freissmuth M, et al. Handling of intracellular K+ determines voltage dependence of plasmalemmal monoamine transporter function. Elife. 2021;10:e67996.
pubmed: 34061030
pmcid: 8192120
doi: 10.7554/eLife.67996
Bhat S, Hasenhuetl PS, Kasture A, El-Kasaby A, Baumann MH, Blough BE, et al. Conformational state interactions provide clues to the pharmacochaperone potential of serotonin transporter partial substrates. J Biol Chem. 2017;292:16773–86.
pubmed: 28842491
pmcid: 5633137
doi: 10.1074/jbc.M117.794081
Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, et al. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT2A serotonin receptor but does not participate in activation via a ‘salt-bridge disruption’ mechanism. J Pharm Exp Ther 1996;293:735–46.
Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharm Rev. 2011;63:585–640.
pubmed: 21752877
doi: 10.1124/pr.108.000869
Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700–6.
pubmed: 36795823
pmcid: 10108900
doi: 10.1126/science.adf0435
Mckenna DJ, Repke DB, Lo L, Peroutka SJ. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 1990;29:193–8.
pubmed: 2139186
doi: 10.1016/0028-3908(90)90001-8
Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharm. 2008;75:17–33.
pubmed: 17977517
doi: 10.1016/j.bcp.2007.07.018
Halberstadt AL, Nichols DE, Geyer MA. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacol (Berl). 2012;221:709–18.
doi: 10.1007/s00213-011-2616-6
López-Arnau R, Camarasa J, Carbó M, Nadal-Gratacós N, Puigseslloses P, Espinosa-Velasco M, et al. 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: from recreational to novel psychotherapeutic drugs. Front Psychiatry. 2022;13:990405.
pubmed: 36262632
pmcid: 9574023
doi: 10.3389/fpsyt.2022.990405
Niello M, Cintulova D, Hellsberg E, Jäntsch K, Holy M, Ayatollahi LH, et al. para-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter. Neuropharmacology. 2019;161:107615.
pubmed: 31028773
doi: 10.1016/j.neuropharm.2019.04.021
Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, et al. Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology. 2015;40:1321–31.
pubmed: 25502630
pmcid: 4397398
doi: 10.1038/npp.2014.325
Glatfelter GC, Pham DNK, Walther D, Golen JA, Chadeayne AR, Baumann MH, et al. Synthesis, structural characterization, and pharmacological activity of novel quaternary salts of 4-substituted tryptamines. ACS Omega. 2022;7:24888–94.
pubmed: 35874244
pmcid: 9301952
doi: 10.1021/acsomega.2c03476
Sandtner W, Stockner T, Hasenhuetl PS, Partilla JS, Seddik A, Zhang Y-W, et al. Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol Pharm. 2016;89:165–75.
doi: 10.1124/mol.115.101394
Reith MEA, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend. 2015;147:1–19.
pubmed: 25548026
doi: 10.1016/j.drugalcdep.2014.12.005
Hilber B, Scholze P, Dorostkar MM, Sandtner W, Holy M, Boehm S, et al. Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology. 2005;49:811–9.
pubmed: 16185723
doi: 10.1016/j.neuropharm.2005.08.008
Bhat S, Newman AH, Freissmuth M. How to rescue misfolded SERT, DAT and NET: targeting conformational intermediates with atypical inhibitors and partial releasers. Biochem Soc Trans. 2019;47:861–74.
pubmed: 31064865
pmcid: 6599159
doi: 10.1042/BST20180512
Maier J, Rauter L, Rudin D, Niello M, Holy M, Schmid D, et al. α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter. Neuropharmacology. 2021;190:108570.
pubmed: 33864800
doi: 10.1016/j.neuropharm.2021.108570
Niello M, Gradisch R, Loland CJ, Stockner T, Sitte HH. Allosteric modulation of neurotransmitter transporters as a therapeutic strategy. Trends Pharm Sci. 2020;41:446–63.
pubmed: 32471654
doi: 10.1016/j.tips.2020.04.006
Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933.
pubmed: 31917152
pmcid: 9191653
doi: 10.1016/j.neuropharm.2019.107933
Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184:2779–92.
pubmed: 33915107
pmcid: 8122087
doi: 10.1016/j.cell.2021.03.043
Pottie E, Stove CP. In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT2AR. J Neurochem 2022;162:39–59.
pubmed: 34978711
doi: 10.1111/jnc.15570
Poulie CBM, Pottie E, Simon IA, Harpsøe K, D’Andrea L, Komarov IV, et al. Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2AReceptor Agonists. J Med Chem. 2022;65:12031–43.
pubmed: 36099411
pmcid: 9511481
doi: 10.1021/acs.jmedchem.2c00702
Araújo AM, Carvalho F, Bastos M, de L, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015;89:1151–73.
pubmed: 25877327
doi: 10.1007/s00204-015-1513-x
Halberstadt AL, Koedood L, Powell SB, Geyer MA. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol. 2011;25:1548–61.
pubmed: 21148021
doi: 10.1177/0269881110388326
Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26:756–66.
pubmed: 26875114
doi: 10.1016/j.euroneuro.2016.01.005
Berendsen HHG, Broekkamp CLE. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharm. 1990;101:667–73.
doi: 10.1111/j.1476-5381.1990.tb14138.x
Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharm Biochem Behav. 2008;88:358–65.
doi: 10.1016/j.pbb.2007.09.007
Leonard JB, Anderson B, Klein-Schwartz W. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol. 2018;32:1286–94.
pubmed: 30182795
doi: 10.1177/0269881118793086
Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001;890:23–31.
pubmed: 11164765
doi: 10.1016/S0006-8993(00)03020-1
Bill DJ, Knight M, Forster EA, Fletche A. Direct evidence for an important species difference in the mechanism of 8‐OH‐DPAT‐induced hypothermia. Br J Pharm. 1991;103:1857–64.
doi: 10.1111/j.1476-5381.1991.tb12342.x
Cryan JF, Kelliher P, Kelly JP, Leonard BE. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: Modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J Psychopharmacol. 1999;13:278–83.
pubmed: 10512084
doi: 10.1177/026988119901300310
Newman-Tancredi A, Depoortère R, Carilla-Durand E, Tarayre JP, Kleven M, Koek W, et al. NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats. Pharm Biochem Behav. 2018;165:56–62.
doi: 10.1016/j.pbb.2017.11.002
Hedlund PB, Kelly L, Mazur C, Lovenberg T, Sutcliffe JG, Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur J Pharm. 2004;487:125–32.
doi: 10.1016/j.ejphar.2004.01.031
Abiero A, Ryu IS, Botanas CJ, Custodio RJP, Sayson LV, Kim M, et al. Four novel synthetic tryptamine analogs induce head-twitch responses and increase 5-HTR2a in the prefrontal cortex in mice. Biomol Ther. 2020;28:83–91.
doi: 10.4062/biomolther.2019.049
Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology. 2006;189:319–29.
pubmed: 17013638
doi: 10.1007/s00213-006-0566-1